Kymab is discovering and developing fully human monoclonal antibody therapeutics using our pioneering Kymouse™ platform. We are building a rich pipeline of assets in four therapeutic spaces: immuno-oncology, inflammation, haematology and infectious diseases.

The Kymouse strains have more base-pairs of the human immunoglobulin genes than any other model. Their performance is exceptional: virtually every mouse responds to challenge, producing high-titre polyclonal antibodies to a variety of antigens including highly conserved human antigens.

Company Growth (employees)
Babraham, GB
Size (employees)
119 (est)+5%
Kymab was founded in 2009 and is headquartered in Babraham, GB

Kymab Office Locations

Kymab has an office in Babraham
Babraham, GB (HQ)
Meditrina Building, 260 Babraham Research Campus

Kymab Data and Metrics

Summary Metrics

Founding Date


Total Funding

$220.4 m

Latest funding size

$100 m

Time since last funding

8 months


Kymab's latest funding round in November 2016 was reported to be $100 m. In total, Kymab has raised $220.4 m

Kymab Company Life and Culture

You may also be interested in